Supplementary Figure S2 from JAB-3312, a Potent Allosteric SHP2 Inhibitor That Enhances the Efficacy of RTK/RAS/MAPK and PD-1 Blockade Therapies

Supplementary Figure S2. The combination of JAB-3312 and glecirasib can enhance the inhibitory effect on the growth of KRASG12C mutant tumors in vitro and in vivo. A. Proliferation inhibition of SW837 human colon cancer cells by JAB-3312, glecirasib, or their combination. B-E. The tumor volume change of SW837 (B), MIA PaCa-2 (C), CR6243 (D), and CR6256 (E) xenograft models during the treatment of JAB-3312, glecirasib, and the two-drug combination. Mean tumor volumes ± SEM were shown.